The European Public Health Alliance organises a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.

The next one is on the 8th of December. The topic is: “Will the EU be a wise investor in biomedical R&D or a passive donor? How can we guarantee a public return on public investment? As the EU considers establishing an Agency comparable to the U.S. Biomedical Advanced Research and Development Authority (BARDA), we will outline a set of recommendations on how to get it right.”

You can register at:

This may interest you